Drug Trial Radar · NCT05709444
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Dec 26, 2022
Primary completion
Apr 26, 2024
Study completion Apr 26, 2024
Sponsor
- Lead sponsor
- Palatin Technologies, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.
Conditions
- Kidney Disease
Interventions
BremelanotideDrug
Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
RAAS inhibition therapyDrug
RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the efficacy of 0.5 mg subcutaneous BMT (given twice a day), used in combination with a subject's maximum tolerated dose of RAAS inhibition therapy, reduces urinary protein by 50% from baseline UP/Cr levels.Time frame: Baseline to after six months of combined therapy (RAAS inhibition therapy plus BMT).
- To determine the incidence of overall adverse events, related adverse events, a composite of adverse events of special interest, serious adverse events, and the incidence of BMT discontinuation.Time frame: Baseline to after six months of combined therapy (RAAS inhibition therapy plus BMT).
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
California Institute of Renal Research
Chula Vista, California
California Institute of Renal Research DBA - Balboa Research
La Mesa, California
Georgia Nephrology, LLC DBA -GA Nephrology Research Institute
Decatur, Georgia
Georgia Nephrology, LLC [DBA] GA Nephrology Research Institute
Lawrenceville, Georgia
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina
Northeast Research Center, LLC
Bethlehem, Pennsylvania
Nephrotex Research Group
Dallas, Texas
Prolator Clinical Research Center
Houston, Texas
Clinical Advancement Center, PLLC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.